Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22782594 | 1.00 | EPHX1 (0.35) | EPHX1GFERCA12CA1CA2 | |
| SCHEMBL16730093 | 1.00 | EPHX1 (0.35) | EPHX1GFERCA12CA1CA2 | |
| SCHEMBL15342690 | 1.00 | EPHX1 (0.35) | EPHX1GFERCA12CA1CA2 | |
| SCHEMBL29880224 | 0.94 | CA12 (0.37) | EPHX1GFERCA12CA1CA2 | |
| SCHEMBL19134631 | 0.94 | CA12 (0.37) | EPHX1GFERCA12CA1CA2 | |
| SCHEMBL16730174 | 0.94 | CA12 (0.37) | EPHX1GFERCA12CA1CA2 | |
| SCHEMBL16622621 | 0.94 | CA12 (0.37) | EPHX1GFERCA12CA1CA2 | |
| SCHEMBL15807993 | 0.92 | EPHX1 (0.33) | EPHX1GFER | |
| SCHEMBL17465347 | 0.90 | EPHX1 (0.35) | EPHX1GFERCA12CA1CA2 | |
| SCHEMBL17465344 | 0.88 | EPHX1 (0.34) | EPHX1GFERCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| CN-110662746-B | Compounds as orally administered prodrugs of beta-lactamase inhibitors, pharmaceutical compositions thereof and use for treating bacterial infections | 阿里萨制药有限公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-3067355-A1 | CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
| WO-2016120752-A1 | A PROCESS FOR PREPARATION OF (2S, 5R)-N-(2-AMINO ETHOXY)-6-(SULFOOXY)-7-OXO-1,6- DIAZABICYCLO [3.2.1] OCTANE-2-CARBOXAMIDE | WOCKHARDT LIMITED (IN) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | EPHX1 1249/4885GFER 667/4885CA12 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.